List view / Grid view
The approval of Pemazyre® (pemigatinib) was based on Phase II…
The approval of Pemazyre® (pemigatinib) was based on Phase II trial results in which the treatment met its primary endpoint, demonstrating a 37 percent overall response rate.
Bristol-Myers Squibb Company and Incyte Corporation announced the establishment of…
28 May 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Incyte Corporation announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen...
Novartis announced that Hervé Hoppenot, President of Novartis Oncology, will…
12 January 2014 | By Novartis
Novartis announced that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect...
"Cancer treatment has been revolutionized by targeted therapies, which have…
4 December 2013 | By Novartis
"Cancer treatment has been revolutionized by targeted therapies, which have established a highly successful approach to the management of many cancers..."
Novartis announced data on its investigational compound LDK378...
3 June 2013 | By Novartis
Novartis announced data on its investigational compound LDK378...
The EC has approved Exjade®...
21 December 2012 | By Novartis
The EC has approved Exjade®...
The US FDA has approved Signifor®...
15 December 2012 | By Novartis
The US FDA has approved Signifor®...
Novartis announced long-term follow-up data...
11 December 2012 | By Novartis
Novartis announced long-term follow-up data...
Latest results from two Phase III clinical trials...
10 December 2012 | By Novartis
Latest results from two Phase III clinical trials...
More than 140 presentations on key data...
28 November 2012 | By Novartis
More than 140 presentations on key data...
The CHMP of the EMA adopted a positive opinion for…
16 November 2012 | By Novartis
The CHMP of the EMA adopted a positive opinion for Exjade®...
Committee votes unanimously in favor of Signifor (pasireotide)...
7 November 2012 | By Novartis
Committee votes unanimously in favor of Signifor (pasireotide)...
European Commission approval for Votubia®...
5 November 2012 | By Novartis
European Commission approval for Votubia®...
Novartis received approval today from the European Commission for Jakavi®...
28 August 2012 | By Novartis
Novartis received approval today from the European Commission for Jakavi®...
The EC has approved Afinitor®...
30 July 2012 | By Novartis
The EC has approved Afinitor®...
